Breaking News

Par Appoints CEO

April 1, 2014

Coughlin to head global manufacturing activities

Terrance J. Coughlin has been named chief operating officer of Par Pharmaceutical Companies, Inc. Mr. Coughlin will be responsible for global manufacturing activities and R&D efforts, as well as the new product selection process. 
 
Mr. Coughlin joins the company from Glenmark Generics, Inc., where he most recently served as president and chief executive officer, and prior to that, served as president. Mr. Coughlin had overall responsibility for the North American, Western European and Eastern European generics businesses, as well as the global API business and generics operations in India. Mr. Coughlin also served as senior vice president at Dr. Reddy's Laboratories, and was responsible for global key accounts for bulk active ingredient operations for North America and Europe. 
 
"Having worked with Terry, I know personally that he is a talented and capable senior manager with a proven track record of success," said Paul V. Campanelli, chief executive officer of Par Pharmaceutical Companies. "Terry's more than 25 years experience in the pharmaceutical industry extends from API to finished dosage, and from R&D to sales and marketing.  He has managed businesses, including manufacturing facilities, in the U.S. and abroad.  Terry's breadth of experience will serve Par well and I am excited to welcome him to our company." 
 
blog comments powered by Disqus
  • API Sourcing Trends

    Kristin Brooks, Contract Pharma||April 11, 2016
    Drug product complexities, quality and regulatory hurdles drive market shift

  • U.S. Pharma Market Trends

    Kristin Brooks, Contract Pharma||April 8, 2016
    CPhI Report sees return of generic and API manufacturing to U.S. market

  • Flexible Manufacturing Strategies

    Kristin Brooks, Contract Pharma||April 4, 2016
    Michael Lehmann of Patheon discusses solutions for pharmaceutical forecasting errors

  • CMO Systems

    CMO Systems

    Philip K. Burns, CRO Consulting||April 5, 2016
    A CMO system includes four aspects of the product lifecycle: regulatory, technical, compliance, and operations.

  • Injectables: The New Oral?

    Injectables: The New Oral?

    Tugrul Kararli, Kurt Sedo, Josef Bossart, PharmaCircle LLC||April 5, 2016
    The growth trend of injectables continues across the pharma landscape.

  • Biopharmaceutical Contract Manufacturing Contract Negotiations

    Biopharmaceutical Contract Manufacturing Contract Negotiations

    William Downey, HighTech Business Decisions||April 5, 2016
    Navigating the complexities of supply agreements.